AcuraStem

AcuraStem is a patient-based biotechnology company focused on developing disease-modifying therapies for neurodegenerative diseases, specifically Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). The company utilizes its proprietary iNeuroRx® technology platform, which employs human patient-derived induced pluripotent stem cells (iPSCs) to model disease pathology and identify novel therapeutic targets. By focusing on core molecular drivers of disease—such as TDP-43 dysfunction—AcuraStem aims to create treatments that are broadly effective across patient populations, rather than limited to rare, genetically defined subtypes. The company has secured significant grant funding from organizations like the California Institute for Regenerative Medicine (CIRM) and maintains strategic partnerships, including a major licensing deal with Takeda.